Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 68788-8208

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68788-8208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil HCl Tablets 5mg (8138f616 83f3 4c47 84ef 1bce2db339f7 00)

Label for Donepezil Hydrochloride Tablets 5mg film-coated oral tablets, a generic version for Aricept. The label indicates a 5 mg strength per tablet and mentions storage conditions and caution against transfer of the drug to others. It shows the labeler as Preferred Pharmaceuticals Inc. and manufacturer as Rising Health, LLC. Directions for use are provided in both English and Spanish.*

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

A line graph depicting the mean change from baseline in ADAS-cog scores over 30 weeks for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The y-axis represents clinical improvement or decline, and the x-axis shows weeks of drug treatment. Data points for 5 mg/day and 10 mg/day doses show clinical improvement sustained over time, while placebo shows clinical decline after week 6.*

FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis represents ADCS-ADL change from baseline, ranging from positive to negative values, and the y-axis shows the cumulative percentage of patients from 0% to 100%. The plot features two curves, one for Donepezil Hydrochloride (filled circles) and one for placebo (open squares), indicating patient response distribution over the ADCS-ADL scale.*

FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

A line graph displaying the SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment with Donepezil Hydrochloride at dosages of 23 mg/day and 10 mg/day. The vertical axis shows SIB change from baseline LS mean with clinical improvement and decline indicated, while the horizontal axis represents weeks of treatment from 0 to 24.*

FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

A cumulative percentage plot showing the distribution of patients by SIB (Severe Impairment Battery) score change from baseline for Donepezil Hydrochloride at 23 mg/day and 10 mg/day doses. The x-axis represents the SIB change from baseline, ranging from +50 to -60, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Two lines compare the effect of the two doses on patient outcomes.*

FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Bar graph comparing the percentage of patients with Donepezil Hydrochloride 23 mg/day and 10 mg/day across different CIBIC-plus rating categories, including markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse.*

FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

A line graph depicting cumulative percentage of patients versus change from baseline in ADAS-cog scores for three treatment groups: placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg. The graph shows the percentage of patients achieving specific points of change, with a table summarizing changes at -7, -4, and 0 points for each group.*

FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

A bar chart comparing the percentage of patients across different CIBIC-plus rating categories for Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups. Categories range from Markedly Improved to Markedly Worse, showing treatment effects distribution by patient response ratings.*

FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

A line graph showing ADAS-cog mean change from baseline over weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The graph indicates clinical improvement or decline, with error bars representing standard error. Donepezil groups show clinical improvement compared to placebo over 15 weeks.*

FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

A cumulative percentage graph showing patients' change from baseline in ADAS-cog scores comparing Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. Lines represent the cumulative percentage of patients with changes in cognitive scores, including annotations at 4 and 7 points improvement. A table summarizes treatment group response percentages for different levels of cognitive change.*

FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

A bar chart illustrating CIBIC-plus ratings, showing the percentage of patients across categories: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The chart compares three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo.*

FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

A line graph showing SIB change from baseline over 6 months of drug treatment, comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis represents mean ± SE change, with clinical improvement upwards and decline downwards. Donepezil shows increased SIB scores over time, while placebo shows a decrease.*

FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

A cumulative percentage graph comparing Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, ranging from 30 to -75, while the y-axis shows the cumulative percentage of patients from 0% to 100%. Donepezil Hydrochloride treatment shows a higher cumulative percentage of patients with greater negative changes compared to placebo, indicating more improvement over baseline.*

FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment, comparing Donepezil Hydrochloride 10 mg/day to placebo. The y-axis represents mean change from baseline scores with clinical improvement upward and decline downward. The x-axis represents months of treatment at 0, 3, and 6 months. Donepezil shows less decline than placebo over time.*

FDA Label Image

Chemical Structure (Donepezil Str)

Chemical structure diagram of Donepezil Hydrochloride, showing the molecular arrangement including methoxy groups, piperidine ring, and phenyl group with HCl.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.